|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Banerjee S and Kaye SB: New strategies in
the treatment of ovarian cancer: Current clinical perspectives and
future potential. Clin Cancer Res. 19:961–968. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mezzanzanica D: Ovarian cancer: A
molecularly insidious disease. Chin J Cancer. 34:1–3. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chien JR, Aletti G, Bell DA, Keeney GL,
Shridhar V and Hartmann LC: Molecular pathogenesis and therapeutic
targets in epithelial ovarian cancer. J Cell Biochem.
102:1117–1129. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hennessy BT, Coleman RL and Markman M:
Ovarian cancer. Lancet. 374:1371–1382. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mendell JT: MicroRNAs: Critical regulators
of development, cellular physiology and malignancy. Cell Cycle.
4:1179–1184. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chong GO, Jeon HS, Han HS, Son JW, Lee YH,
Hong DG, Lee YS and Cho YL: Differential microRNA expression
profiles in primary and recurrent epithelial ovarian cancer.
Anticancer Res. 35:2611–2617. 2015.PubMed/NCBI
|
|
10
|
Llauradó M, Majem B, Altadill T, Lanau L,
Castellví J, Sánchez-Iglesias JL, Cabrera S, De la Torre J,
Díaz-Feijoo B, Pérez-Benavente A, et al: MicroRNAs as prognostic
markers in ovarian cancer. Mol Cell Endocrinol. 390:73–84. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Iorio MV, Visone R, Di Leva G, Donati V,
Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et
al: MicroRNA signatures in human ovarian cancer. Cancer Res.
67:8699–8707. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Taylor DD and Gercel-Taylor C: MicroRNA
signatures of tumor-derived exosomes as diagnostic biomarkers of
ovarian cancer. Gynecol Oncol. 110:13–21. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang S, Lu Z, Unruh AK, Ivan C, Baggerly
KA, Calin GA, Li Z, Bast RC Jr and Le XF: Clinically relevant
microRNAs in ovarian cancer. Mol Cancer Res. 13:393–401. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin Q, Chen T, Lin Q, Lin G, Lin J, Chen G
and Guo L: Serum miR-19a expression correlates with worse prognosis
of patients with non-small cell lung cancer. J Surg Oncol.
107:767–771. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li J, Yang S, Yan W, Yang J, Qin YJ, Lin
XL, Xie RY, Wang SC, Jin W, Gao F, et al: MicroRNA-19 triggers
epithelial-mesenchymal transition of lung cancer cells accompanied
by growth inhibition. Lab Invest. 95:1056–1070. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ohira T, Naohiro S, Nakayama Y, Osaki M,
Okada F, Oshimura M and Kugoh H: miR-19b regulates hTERT mRNA
expression through targeting PITX1 mRNA in melanoma cells. Sci Rep.
5:82012015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang X, Yu H, Lou JR, Zheng J, Zhu H,
Popescu NI, Lupu F, Lind SE and Ding WQ: MicroRNA-19 (miR-19)
regulates tissue factor expression in breast cancer cells. J Biol
Chem. 286:1429–1435. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Baumhoer D, Zillmer S, Unger K, Rosemann
M, Atkinson MJ, Irmler M, Beckers J, Siggelkow H, von Luettichau I,
Jundt G, et al: MicroRNA profiling with correlation to gene
expression revealed the oncogenic miR-17-92 cluster to be
up-regulated in osteosarcoma. Cancer Genet. 205:212–219. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang F, Li T, Zhang B, Li H, Wu Q, Yang L,
Nie Y, Wu K, Shi Y and Fan D: MicroRNA-19a/b regulates multidrug
resistance in human gastric cancer cells by targeting PTEN. Biochem
Biophys Res Commun. 434:688–694. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Javadi S, Ganeshan DM, Qayyum A, Iyer RB
and Bhosale P: Ovarian cancer, the revised FIGO staging system, and
the role of imaging. AJR Am J Roentgenol. 206:1351–1360. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ma W, Yu Q, Jiang J, DU X, Huang L, Zhao L
and Zhou QI: miR-517a is an independent prognostic marker and
contributes to cell migration and invasion in human colorectal
cancer. Oncol Lett. 11:2583–2589. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shen Y, Shen R, Ge L, Zhu Q and Li F:
Fibrillar type I collagen matrices enhance metastasis/invasion of
ovarian epithelial cancer via β1 integrin and PTEN signals. Int J
Gynecol Cancer. 22:1316–1324. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu H, Pan Y, Han X, Liu J and Li R:
MicroRNA-216a promotes the metastasis and epithelial-mesenchymal
transition of ovarian cancer by suppressing the PTEN/AKT pathway.
Onco Targets Ther. 10:2701–2709. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lou Y, Yang X, Wang F, Cui Z and Huang Y:
MicroRNA-21 promotes the cell proliferation, invasion and migration
abilities in ovarian epithelial carcinomas through inhibiting the
expression of PTEN protein. Int J Mol Med. 26:819–827. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Georgescu MM: PTEN tumor suppressor
network in PI3K-Akt pathway control. Genes Cancer. 1:1170–1177.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lengyel E: Ovarian cancer development and
metastasis. Am J Pathol. 177:1053–1064. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mezzanzanica D, Bagnoli M, De Cecco L,
Valeri B and Canevari S: Role of microRNAs in ovarian cancer
pathogenesis and potential clinical implications. Int J Biochem
Cell Biol. 42:1262–1272. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li X, Xie W, Xie C, Huang C, Zhu J, Liang
Z, Deng F, Zhu M, Zhu W, Wu R, et al: Curcumin modulates
miR-19/PTEN/AKT/p53 Axis to suppress bisphenol A-induced MCF-7
breast cancer cell proliferation. Phytother Res. 28:1553–1560.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
JiaZeng X: MicroRNA and tumor metastasis.
Cancer Res Clinic. 21:65–67. 2009.
|
|
32
|
Yang H, Kong W, He L, Zhao JJ, O'Donnell
JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV and Cheng JQ:
MicroRNA expression profiling in human ovarian cancer: miR-214
induces cell survival and cisplatin resistance by targeting PTEN.
Cancer Res. 68:425–433. 2008. View Article : Google Scholar : PubMed/NCBI
|
